Professional Special Situation Investor, TripleS Special Situation Investing

Triple S Special Situations Investing

Professional Special Situation Investor

TripleS Special Situation Investing

Professional Special Situation Investor with over 20 years of experience.

Equity Bottom-Up

SpringWorks Therapeutics Inc / Equity Bottom-Up

<ul><li>SpringWorks Therapeutics represents a highly attractive risk-reward opportunity with substantial upside potential from an imminent acquisition.</li><li>The company is currently in play with confirmed acquisition talks and multiple signs pointing to a transaction at a significant premium to current levels.</li><li><strong>Current price:</strong> $50, <strong>Target price: </strong>$70-85, representing approximately 50% upside with limited downside risk.</li></ul>

SpringWorks Therapeutics represents a highly attractive risk-reward opportunity with substantial upside potential from an imminent acquisition.The company is currently in play with confirmed acquisition talks and multiple signs pointing to a transaction at a significant premium to current levels.Current price: $50, Target price: $70-85, representing approximately 50% upside with limited downside risk.

SpringWorks Therapeutics (SWTX): A Compelling Biotech Buyout Thesis with Limited Downside

Event-Driven Investment Opportunities, Special Situation Investments

Special Situation Investments

Event-Driven Investment Opportunities

Focus on event-driven trades and low risk arbitrage opportunities with short term catalysts

Event-Driven

SpringWorks Therapeutics Inc / Event-Driven

<ul><li>SpringWorks Therapeutics is in advanced acquisition talks with Merck KGaA, following FDA approval for its drug Gomekli.</li><li>Merck's acquisition strategy focuses on low-risk, value-creating oncology deals, aligning with SpringWorks' FDA-approved treatments.</li><li>Estimated peak sales for SpringWorks' drugs range from $600m to $1bn, suggesting a potential $85/share valuation.</li></ul>

SpringWorks Therapeutics is in advanced acquisition talks with Merck KGaA, following FDA approval for its drug Gomekli.Merck's acquisition strategy focuses on low-risk, value-creating oncology deals, aligning with SpringWorks' FDA-approved treatments.Estimated peak sales for SpringWorks' drugs range from $600m to $1bn, suggesting a potential $85/share valuation.

SpringWorks Therapeutics in Advanced Acquisition Talks with Merck KGaA Amid FDA Approval and Growth Potential

<ul><li>SpringWorks Therapeutics (SWTX) is in late-stage acquisition talks with Merck KGaA, with a potential buyout offer at $85/share.</li><li>Liquidia (LQDA) had its FDA case denied, delaying Yutrepia's market entry until May 2025, with commercialization on track.</li><li>ContextLogic (LOGC) received a $150m strategic investment from BC Partners, enhancing its cash balance and NOL monetization potential.</li></ul>

SpringWorks Therapeutics (SWTX) is in late-stage acquisition talks with Merck KGaA, with a potential buyout offer at $85/share.Liquidia (LQDA) had its FDA case denied, delaying Yutrepia's market entry until May 2025, with commercialization on track.ContextLogic (LOGC) received a $150m strategic investment from BC Partners, enhancing its cash balance and NOL monetization potential.

SSI Weekly Newsletter Highlights: SWTX and NATH Potential Buyouts, LQDA FDA Update and More

Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Thematic (Sector/Industry)

<ul><li>Biotech fared better than pharma, as macro trends mostly favored growth stocks and LLY weakness pressured the large cap group.</li><li>M&amp;A activity also helped biotech, with NVS acquiring RLGS at a 108% premium and MKKGY buying SWTX after months of speculation.</li><li>Sentiment remained cautious among industry leaders, with another potential sign of regulatory disruption as the FDA missed Stealth’s (private) PDUFA date.</li></ul>

Biotech fared better than pharma, as macro trends mostly favored growth stocks and LLY weakness pressured the large cap group.M&amp;A activity also helped biotech, with NVS acquiring RLGS at a 108% premium and MKKGY buying SWTX after months of speculation.Sentiment remained cautious among industry leaders, with another potential sign of regulatory disruption as the FDA missed Stealth’s (private) PDUFA date.

Biopharma Week in Review - Macro and M&A Boost Biotech; NVO Moves to Slow LLY Obesity Lead

<ul>
<li>Kronos Bio (KRON) signed an acquisition agreement at $0.57/share plus a CVR, below expected net cash value.</li>
<li>Sage Therapeutics (SAGE) reported Q1 revenue growth, ongoing strategic review, and management urged to cut costs or sell.</li>
<li>DMC Global (BOOM) exceeded Q1 guidance but faces uncertain outlook due to tariffs and demand destruction.</li>
</ul>


Kronos Bio (KRON) signed an acquisition agreement at $0.57/share plus a CVR, below expected net cash value.
Sage Therapeutics (SAGE) reported Q1 revenue growth, ongoing strategic review, and management urged to cut costs or sell.
DMC Global (BOOM) exceeded Q1 guidance but faces uncertain outlook due to tariffs and demand destruction.


Weekly Financial Insights: KRON Buyout, SAGE Earnings, BOOM Performance and More

United States

SpringWorks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company acquires, develops, and commercializes medicines for patients suffering various diseases and cancer. SpringWorks Therapeutics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

SpringWorks Therapeutics Inc (SWTX US)

SpringWorks Therapeutics (SWTX): A Compelling Biotech Buyout Thesis with Limited Downside

SpringWorks Therapeutics represents a highly attractive risk-reward opportunity with substantial upside potential from an imminent acquisition.

Triple S Special Situations Investing

SpringWorks Therapeutics in Advanced Acquisition Talks with Merck KGaA Amid FDA Approval and Growth Potential

SpringWorks Therapeutics is in advanced acquisition talks with Merck KGaA, following FDA approval for its drug Gomekli.

Special Situation Investments

Biopharma Week in Review - Macro and M&A Boost Biotech; NVO Moves to Slow LLY Obesity Lead

Biotech fared better than pharma, as macro trends mostly favored growth stocks and LLY weakness pressured the large cap group.

Water Tower Research

Weekly Financial Insights: KRON Buyout, SAGE Earnings, BOOM Performance and More

Kronos Bio (KRON) signed an acquisition agreement at $0.57/share plus a CVR, below expected net cash value. Sage Therapeutics (SAGE) reported Q1...

Special Situation Investments

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)